Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
339.04
-0.62 (-0.18%)
At close: Nov 12, 2024, 4:00 PM
340.00
+0.96 (0.28%)
After-hours: Nov 12, 2024, 5:32 PM EST
Company Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 376 |
| CEO | William Sibold |
Contact Details
Address: Four Tower Bridge, Suite 200 West Conshohocken, Pennsylvania 19428 United States | |
| Phone | 267 824 2827 |
| Website | madrigalpharma.com |
Stock Details
| Ticker Symbol | MDGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001157601 |
| CUSIP Number | 558868105 |
| ISIN Number | US5588681057 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William J. Sibold | Chief Executive Officer, President and Director |
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research and Development and Director |
| Carole Huntsman | Chief Commercial Officer |
| Mardi C. Dier | Chief Financial Officer and Senior Vice President |
| Mark Underwood | Senior Vice President of Business Planning and Operations |
| Ronald Filippo | Chief Information Officer |
| Tina E. Ventura | Chief Investor Relations Officer |
| Shannon Kelley | Chief Compliance Office and General Counsel |
| Clint Wallace | Chief Human Resources Officer |
| Edward Chiang | Senior Vice President of Clinical and Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | 144 | Filing |
| Nov 1, 2024 | 144 | Filing |
| Oct 31, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Sep 10, 2024 | 144 | Filing |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 144 | Filing |